(VIANEWS) – The Market ended the session with ULTIMOVACS (ULTI.OL) rising 9.37% to kr108.60 on Friday while Oslo Børs Benchmark Index_GI rose 0.91% to kr1,263.81.
ULTIMOVACS’s last close was kr99.30, 44.4% under its 52-week high of kr178.60.
About ULTIMOVACS
Ultimovacs ASA, a biotech company, develops immunotherapies against cancers. Its lead product candidate is UV1, a peptide-based cancer vaccine that induces a specific T cell response against the universal cancer antigen telomerase. The company was incorporated in 2011 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, ULTIMOVACS has a trailing twelve months EPS of kr-5.5.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -40.11%.
Moving Average
ULTIMOVACS’s value is way above its 50-day moving average of kr87.65 and higher than its 200-day moving average of kr100.74.
Yearly Top and Bottom Value
ULTIMOVACS’s stock is valued at kr108.60 at 22:35 EST, way below its 52-week high of kr178.60 and way higher than its 52-week low of kr67.00.
More news about ULTIMOVACS (ULTI.OL).
